Prostacyclin is a potent vasodilator and platelet inhibitor produced by vascular endothelium. Endogenous production of prostacyclin under physiologic conditions is extremely low, far below the capacity of vascular tissue to generate this substance in response to stimulation in vitro. This may reflect a low frequency or intensity of stimulation of prostacyclin production. We postulated that if prostacyclin does act as an endogenous platelet-inhibitory agent, it should be produced in greater amounts in a clinical setting in which platelet-vascular interactions are likely to be increased. To test this hypothesis, we examined prostacyclin biosynthesis in patients with severe atherosclerosis and evidence of platelet activation in vivo. Excretion of 2,3-dinor-6-keto-prostaglandin F1 alpha, a major urinary prostacyclin metabolite, was significantly higher in 9 patients with severe atherosclerosis and evidence of platelet activation (251 to 1859 pg per milligram of creatinine) than in 54 healthy volunteers (45 to 219 pg per milligram of creatinine; P less than 0.001). This difference represented an alteration in biosynthesis rather than in metabolism, since the fractional conversion of infused prostacyclin to the dinor metabolite was identical in both groups. Prostacyclin production may be low in healthy persons because there is almost no stimulus for its production but enhanced in patients with severe atherosclerosis as a consequence of platelet interactions with endothelium or other vascular insults. These observations are compatible with a role for prostacyclin as a local regulator of platelet-vascular interactions.
This article has been cited by other articles:
Song, W.-L., Wang, M., Ricciotti, E., Fries, S., Yu, Y., Grosser, T., Reilly, M., Lawson, J. A., FitzGerald, G. A.
(2008). Tetranor PGDM, an Abundant Urinary Metabolite Reflects Biosynthesis of Prostaglandin D2 in Mice and Humans. J. Biol. Chem.
283: 1179-1188
[Abstract][Full Text]
Tan, X., Essengue, S., Talreja, J., Reese, J., Stechschulte, D. J., Dileepan, K. N.
(2007). Histamine Directly and Synergistically with Lipopolysaccharide Stimulates Cyclooxygenase-2 Expression and Prostaglandin I2 and E2 Production in Human Coronary Artery Endothelial Cells. J. Immunol.
179: 7899-7906
[Abstract][Full Text]
Joshi, G. P., Gertler, R., Fricker, R.
(2007). Cardiovascular Thromboembolic Adverse Effects Associated with Cyclooxygenase-2 Selective Inhibitors and Nonselective Antiinflammatory Drugs. Anesth. Analg.
105: 1793-1804
[Abstract][Full Text]
Antman, E. M., Bennett, J. S., Daugherty, A., Furberg, C., Roberts, H., Taubert, K. A.
(2007). Use of Nonsteroidal Antiinflammatory Drugs: An Update for Clinicians: A Scientific Statement From the American Heart Association. Circulation
115: 1634-1642
[Full Text]
Anning, P. B., Coles, B., Morton, J., Wang, H., Uddin, J., Morrow, J. D., Dey, S. K., Marnett, L. J., O'Donnell, V. B.
(2006). Nitric oxide deficiency promotes vascular side effects of cyclooxygenase inhibitors. Blood
108: 4059-4062
[Abstract][Full Text]
Chaiamnuay, S., Allison, J. J., Curtis, J. R.
(2006). Risks versus benefits of cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs.. Am J Health Syst Pharm
63: 1837-1851
[Abstract][Full Text]
Wang, M., Zukas, A. M., Hui, Y., Ricciotti, E., Pure, E., FitzGerald, G. A.
(2006). Deletion of microsomal prostaglandin E synthase-1 augments prostacyclin and retards atherogenesis. Proc. Natl. Acad. Sci. USA
103: 14507-14512
[Abstract][Full Text]
Patrignani, P., Di Febbo, C., Tacconelli, S., Moretta, V., Baccante, G., Sciulli, M. G., Ricciotti, E., Capone, M. L., Antonucci, I., Guglielmi, M. D., Stuppia, L., Porreca, E.
(2006). Reduced thromboxane biosynthesis in carriers of toll-like receptor 4 polymorphisms in vivo. Blood
107: 3572-3574
[Abstract][Full Text]
Vonkeman, H. E, Brouwers, J. R B J, van de Laar, M. A F J
(2006). Understanding the NSAID related risk of vascular events.. BMJ
332: 895-898
[Full Text]
Deeb, R. S., Shen, H., Gamss, C., Gavrilova, T., Summers, B. D., Kraemer, R., Hao, G., Gross, S. S., Laine, M., Maeda, N., Hajjar, D. P., Upmacis, R. K.
(2006). Inducible Nitric Oxide Synthase Mediates Prostaglandin H2 Synthase Nitration and Suppresses Eicosanoid Production. Am. J. Pathol.
168: 349-362
[Abstract][Full Text]
Antman, E. M., DeMets, D., Loscalzo, J.
(2005). Cyclooxygenase Inhibition and Cardiovascular Risk. Circulation
112: 759-770
[Full Text]
Konstantinopoulos, P. A., Lehmann, D. F.
(2005). The Cardiovascular Toxicity of Selective and Nonselective Cyclooxygenase Inhibitors: Comparisons, Contrasts, and Aspirin Confounding. J Clin Pharmacol
45: 742-750
[Abstract][Full Text]
Bennett, J. S., Daugherty, A., Herrington, D., Greenland, P., Roberts, H., Taubert, K. A.
(2005). The Use of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): A Science Advisory From the American Heart Association. Circulation
111: 1713-1716
[Full Text]
Schror, K., Mehta, P., Mehta, J. L.
(2005). Cardiovascular Risk of Selective Cyclooxygenase-2 Inhibitors. J CARDIOVASC PHARMACOL THER
10: 95-101
[Abstract]
Wu, K. K., Liou, J.-Y., Cieslik, K.
(2005). Transcriptional Control of COX-2 via C/EBP{beta}. Arterioscler. Thromb. Vasc. Bio.
25: 679-685
[Abstract][Full Text]
Vinals, M., Bermudez, I., Llaverias, G., Alegret, M., Sanchez, R. M., Vazquez-Carrera, M., Laguna, J. C.
(2005). Aspirin increases CD36, SR-BI, and ABCA1 expression in human THP-1 macrophages. Cardiovasc Res
66: 141-149
[Abstract][Full Text]
Egan, K. M., Wang, M., Lucitt, M. B., Zukas, A. M., Pure, E., Lawson, J. A., FitzGerald, G. A.
(2005). Cyclooxygenases, Thromboxane, and Atherosclerosis: Plaque Destabilization by Cyclooxygenase-2 Inhibition Combined With Thromboxane Receptor Antagonism. Circulation
111: 334-342
[Abstract][Full Text]
Upmacis, R. K., Deeb, R. S., Resnick, M. J., Lindenbaum, R., Gamss, C., Mittar, D., Hajjar, D. P.
(2004). Involvement of the mitogen-activated protein kinase cascade in peroxynitrite-mediated arachidonic acid release in vascular smooth muscle cells. Am. J. Physiol. Cell Physiol.
286: C1271-C1280
[Abstract][Full Text]
Dai, W., Kloner, R. A.
(2004). Relationship Between Cyclooxygenase-2 Inhibition and Thrombogenesis. J CARDIOVASC PHARMACOL THER
9: 51-59
[Abstract]
Belton, O. A., Duffy, A., Toomey, S., Fitzgerald, D. J.
(2003). Cyclooxygenase Isoforms and Platelet Vessel Wall Interactions in the Apolipoprotein E Knockout Mouse Model of Atherosclerosis. Circulation
108: 3017-3023
[Abstract][Full Text]
Belton, O., Fitzgerald, D.
(2003). Cyclooxygenase-2 inhibitors and atherosclerosis. J Am Coll Cardiol
41: 1820-1822
[Full Text]
Cheng, Y., Austin, S. C., Rocca, B., Koller, B. H., Coffman, T. M., Grosser, T., Lawson, J. A., FitzGerald, G. A.
(2002). Role of Prostacyclin in the Cardiovascular Response to Thromboxane A2. Science
296: 539-541
[Abstract][Full Text]
Whigham, L. D., Higbee, A., Bjorling, D. E., Park, Y., Pariza, M. W., Cook, M. E.
(2002). Decreased antigen-induced eicosanoid release in conjugated linoleic acid-fed guinea pigs. Am. J. Physiol. Regul. Integr. Comp. Physiol.
282: R1104-R1112
[Abstract][Full Text]
Eldor, A., Rachmilewitz, E. A.
(2002). The hypercoagulable state in thalassemia. Blood
99: 36-43
[Abstract][Full Text]
Degraeve, F., Bolla, M., Blaie, S., Creminon, C., Quere, I., Boquet, P., Levy-Toledano, S., Bertoglio, J., Habib, A.
(2001). Modulation of COX-2 Expression by Statins in Human Aortic Smooth Muscle Cells. INVOLVEMENT OF GERANYLGERANYLATED PROTEINS. J. Biol. Chem.
276: 46849-46855
[Abstract][Full Text]
FitzGerald, G. A., Patrono, C.
(2001). The Coxibs, Selective Inhibitors of Cyclooxygenase-2. NEJM
345: 433-442
[Full Text]
Tarr, F. I., Sasvari, M., Dudas, G., Kroo, M., Somogyi, A., Tomcsanyi, I.
(2001). Quantitative measurement of endothelium derived nitric oxide production of the internal mammary artery bypass graft during extracorporeal circulation. Eur. J. Cardiothorac. Surg.
19: 653-656
[Abstract][Full Text]
Mardini, I. A., FitzGerald, G. A.
(2001). Selective Inhibitors of Cyclooxygenase-2: A Growing Class of Anti-Inflammatory Drugs. Mol. Interv.
1: 30-38
[Abstract][Full Text]
Whitehead, A. S., FitzGerald, G. A.
(2001). Twenty-First Century Phox: Not Yet Ready for Widespread Screening. Circulation
103: 7-9
[Full Text]
Pratico, D., Cyrus, T., Li, H., FitzGerald, G. A.
(2000). Endogenous biosynthesis of thromboxane and prostacyclin in 2 distinct murine models of atherosclerosis. Blood
96: 3823-3826
[Abstract][Full Text]
Osanai, T., Fujita, N., Fujiwara, N., Nakano, T., Takahashi, K., Guan, W., Okumura, K.
(2000). Cross talk of shear-induced production of prostacyclin and nitric oxide in endothelial cells. Am. J. Physiol. Heart Circ. Physiol.
278: H233-H238
[Abstract][Full Text]
Iwai, N., Katsuya, T., Ishikawa, K., Mannami, T., Ogata, J., Higaki, J., Ogihara, T., Tanabe, T., Baba, S.
(1999). Human Prostacyclin Synthase Gene and Hypertension : The Suita Study. Circulation
100: 2231-2236
[Abstract][Full Text]
Duffy, S. J., Castle, S. F., Harper, R. W., Meredith, I. T.
(1999). Contribution of Vasodilator Prostanoids and Nitric Oxide to Resting Flow, Metabolic Vasodilation, and Flow-Mediated Dilation in Human Coronary Circulation. Circulation
100: 1951-1957
[Abstract][Full Text]
Mehta, J.L, Li, D.Y
(1999). Inflammation in ischemic heart disease: Response to tissue injury or a pathogenetic villain?. Cardiovasc Res
43: 291-299
[Full Text]
Catella-Lawson, F., McAdam, B., Morrison, B. W., Kapoor, S., Kujubu, D., Antes, L., Lasseter, K. C., Quan, H., Gertz, B. J., FitzGerald, G. A.
(1999). Effects of Specific Inhibition of Cyclooxygenase-2 on Sodium Balance, Hemodynamics, and Vasoactive Eicosanoids. J. Pharmacol. Exp. Ther.
289: 735-741
[Abstract][Full Text]
Baker, C. S. R., Hall, R. J. C., Evans, T. J., Pomerance, A., Maclouf, J., Creminon, C., Yacoub, M. H., Polak, J. M.
(1999). Cyclooxygenase-2 Is Widely Expressed in Atherosclerotic Lesions Affecting Native and Transplanted Human Coronary Arteries and Colocalizes With Inducible Nitric Oxide Synthase and Nitrotyrosine Particularly in Macrophages. Arterioscler. Thromb. Vasc. Bio.
19: 646-655
[Abstract][Full Text]
Bode-Boger, S. M, Boger, R. H, Kienke, S., Bohme, M., Phivthong-ngam, L., Tsikas, D., Frolich, J. C
(1998). Chronic dietary supplementation with L-arginine inhibits platelet aggregation and thromboxane A2 synthesis in hypercholesterolaemic rabbits in vivo. Cardiovasc Res
37: 756-764
[Abstract][Full Text]
Davi, G., Gresele, P., Violi, F., Basili, S., Catalano, M., Giammarresi, C., Volpato, R., Nenci, G. G., Ciabattoni, G., Patrono, C.
(1997). Diabetes Mellitus, Hypercholesterolemia, and Hypertension but Not Vascular Disease Per Se Are Associated With Persistent Platelet Activation In Vivo : Evidence Derived From the Study of Peripheral Arterial Disease. Circulation
96: 69-75
[Abstract][Full Text]
Li, Z., Mao, H. Z., Abboud, F. M., Chapleau, M. W.
(1996). Oxygen-Derived Free Radicals Contribute to Baroreceptor Dysfunction in Atherosclerotic Rabbits. Circ. Res.
79: 802-811
[Abstract][Full Text]
Carreras, L. O., Maclouf, J.
(1994). Antiphospholipid Antibodies Eicosanoids. Lupus
3: 271-273
Ware, J. A., Heistad, D. D.
(1993). Platelet-Endothelium Interactions. NEJM
328: 628-635
[Full Text]
Smyth, E. M., Austin, S. C., Reilly, M. P., FitzGerald, G. A.
(2000). Internalization and Sequestration of the Human Prostacyclin Receptor. J. Biol. Chem.
275: 32037-32045
[Abstract][Full Text]
Pratico, D., Tillmann, C., Zhang, Z.-B., Li, H., FitzGerald, G. A.
(2001). Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice. Proc. Natl. Acad. Sci. USA
98: 3358-3363
[Abstract][Full Text]
